Understanding Invega Sustenna Prescribing Information: Dosage, Administration, and Safety
Invega Sustenna is a long-acting injectable antipsychotic medication used in the treatment of schizophrenia and schizoaffective disorder. Understanding the prescribing information for Invega Sustenna is critical to ensure safe and effective medication use. In this article, we’ll discuss the dosage, administration, and safety considerations for Invega Sustenna.
Dosage
Invega Sustenna is available in four different dosage strengths: 39 mg, 78 mg, 117 mg, and 156 mg. The appropriate dose will be determined by a healthcare provider based on the patient’s condition and response to treatment. It’s important to note that the maximum recommended dose of Invega Sustenna is 234 mg, and doses greater than this should be avoided.
Administration
Invega Sustenna is administered by a healthcare provider via a deep intramuscular injection into the deltoid or gluteal muscle. The injection site should be rotated with every dose to reduce the risk of injection site reactions. It’s important to note that Invega Sustenna should only be administered by a healthcare provider who is trained in the appropriate injection technique.
Safety Considerations
Invega Sustenna carries several safety considerations that healthcare providers and patients should be aware of. One potential side effect of Invega Sustenna is tardive dyskinesia, which is a potentially irreversible movement disorder. Patients and healthcare providers should monitor for signs of tardive dyskinesia, which can include involuntary movements of the face and body.
Additionally, Invega Sustenna can cause a range of other side effects, including weight gain, increased blood sugar levels, and elevated prolactin levels. Healthcare providers should regularly monitor these parameters in patients receiving Invega Sustenna.
Invega Sustenna is contraindicated in patients with a history of neuroleptic malignant syndrome (NMS) or hypersensitivity to paliperidone or risperidone. Patients should also be screened for cardiovascular risk factors prior to starting treatment with Invega Sustenna.
Conclusion
Invega Sustenna is a commonly used long-acting injectable antipsychotic medication for the treatment of schizophrenia and schizoaffective disorder. Understanding the prescribing information for Invega Sustenna, including dosage, administration, and safety considerations, is critical to ensure safe and effective medication use. Healthcare providers and patients should work together to monitor for potential side effects and mitigate any risks associated with Invega Sustenna use.
